2-iodo-5-fluoro-3-methylbenzoic acid | 1415764-25-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-iodo-5-fluoro-3-methylbenzoic acid
• 英文别名: 5-fluoro-2-iodo-3-methylbenzoic acid；5-Fluoro-2-iodo-3-methylbenzoic acid
• CAS: 1415764-25-8
• 化学式: C₈H₆FIO₂
• 分子量: 280.037
• InChiKey: PAZAVFQHUJMVOF-UHFFFAOYSA-N

物化性质

• 沸点：
  319.5±42.0 °C(Predicted)
• 密度：
  1.937±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-iodo-5-fluoro-3-methylbenzoic acid 在 氯化亚砜 、 偶氮二甲酸二异丙酯 、 三乙胺 、 N,N-二甲基甲酰胺 、 三苯基膦 作用下， 以 四氢呋喃 、 1,4-二氧六环 为溶剂， 反应 39.0h， 生成 (4S,5S)-2-(5-fluoro-2-iodo-3-methylphenyl)-4,5-dihydro-4-methyl-5-phenyloxazole
  参考文献：
  名称：

  Catalytic Enantioselective α-Tosyloxylation of Ketones Using Iodoaryloxazoline Catalysts: Insights on the Stereoinduction Process

  摘要：

  A family of iodooxazoline catalysts was developed to promote the iodine(III)-mediated alpha-tosyloxylation of ketone derivatives. The alpha-tosyloxy ketones produced are polyvalent chiral synthons. Through this study, we have unearthed a unique mode of stereoinduction from the chiral oxazoline moiety, where the stereogenic center alpha to the oxazoline oxygen atom is significant. Computational chemistry was used to rationalize the stereoinduction process. The catalysts presented promote currently among the best levels of activity and selectivity for this transformation. Evaluation of the scope of the reaction is presented.

  DOI：

  10.1021/jo302393u
• 作为产物：
  描述：

  3-氟-5-甲基苯甲酸 在 硫酸 、 potassium nitrate 、 tin(ll) chloride 作用下， 以 水 、 乙酸乙酯 为溶剂， 反应 18.17h， 生成 2-iodo-5-fluoro-3-methylbenzoic acid
  参考文献：
  名称：

  [EN] DIFLUOROPYRROLIDINES AS OREXIN RECEPTOR MODULATORS
  [FR] DIFLUOROPYRROLIDINES EN TANT QUE MODULATEURS DES RÉCEPTEURS DE L'OREXINE

  摘要：

  本申请涉及某些二氟吡咯烷化合物，含有它们的药物组合物，以及使用它们的方法，包括用于治疗物质成瘾、惊恐障碍、焦虑、创伤后应激障碍、疼痛、抑郁症、季节性情感障碍、进食障碍或高血压的方法。

  公开号：

  WO2016025669A1

文献信息

• [EN] DIFLUOROPYRROLIDINES AS OREXIN RECEPTOR MODULATORS<br/>[FR] DIFLUOROPYRROLIDINES EN TANT QUE MODULATEURS DES RÉCEPTEURS DE L'OREXINE
  申请人：EOLAS THERAPEUTICS INC

  公开号：WO2016025669A1

  公开（公告）日：2016-02-18

  The present application relates to certain difluoropyrrolidine compounds, pharmaceutical compositions containing them, and methods of using them, including methods for treating substance addiction, panic disorder, anxiety, post-traumatic stress disorder, pain, depression, seasonal affective disorder, an eating disorder, or hypertension.

  本申请涉及某些二氟吡咯烷化合物，含有它们的药物组合物，以及使用它们的方法，包括用于治疗物质成瘾、惊恐障碍、焦虑、创伤后应激障碍、疼痛、抑郁症、季节性情感障碍、进食障碍或高血压的方法。
• SUBSTITUTED PROLINES / PIPERIDINES AS OREXIN RECEPTOR ANTAGONISTS
  申请人：Eolas Therapeutics, Inc.

  公开号：US20140364433A1

  公开（公告）日：2014-12-11

  The present invention is directed to compounds that modulate the bioactivity of an orexin receptor such as OX 1 or OX 2 , or both; to pharmaceutical compositions and combinations comprising a compound of the invention; to methods of treatment of malconditions in patients wherein modulation of an orexin receptor is medically indicated; and to methods of preparation of compounds of the invention. For example, orexin receptor-modulatory compounds of the present invention can be used in treatment of an eating disorder, obesity, alcoholism or an alcohol-related disorder, drug abuse or addiction including addiction to cocaine, opiates, amphetamines, or nicotine, a sleep disorder, a cognitive dysfunction in a psychiatric or neurologic disorder, depression, anxiety, panic disorder, schizophrenia, Alzheimer's disease, Parkinson's disease, Huntington's chorea, headache, migraine, pain, gastrointestinal diseases, epilepsy, inflammations, immune-related diseases, endocrine-related diseases, cancer, hypertension, behavior disorder, mood disorder, manic depression, dementia, sex disorder, psychosexual disorder, or renal disease.

  本发明涉及调节促觉醒素受体（如OX1或OX2，或两者）生物活性的化合物；涉及包含本发明化合物的制药组合物；涉及在医学上调节促觉醒素受体治疗患者疾病的方法；以及涉及制备本发明化合物的方法。例如，本发明的促觉醒素受体调节化合物可用于治疗进食障碍、肥胖症、酗酒或与酒精有关的疾病、药物滥用或成瘾，包括可卡因、鸦片类药物、安非他命或尼古丁成瘾，睡眠障碍、精神或神经障碍中的认知功能障碍、抑郁症、焦虑症、惊恐障碍、精神分裂症、阿尔茨海默病、帕金森病、亨廷顿舞蹈症、头痛、偏头痛、疼痛、肠胃疾病、癫痫、炎症、免疫相关疾病、内分泌相关疾病、癌症、高血压、行为障碍、情绪障碍、躁郁症、痴呆症、性功能障碍、心理性性功能障碍或肾脏疾病的治疗。
• Substituted prolines/piperidines as orexin receptor antagonists
  申请人：Eolas Therapeutics, Inc.

  公开号：US09440982B2

  公开（公告）日：2016-09-13

  The present invention is directed to compounds that modulate the bioactivity of an orexin receptor such as OX1 or OX2, or both; to pharmaceutical compositions and combinations comprising a compound of the invention; to methods of treatment of malconditions in patients wherein modulation of an orexin receptor is medically indicated; and to methods of preparation of compounds of the invention. For example, orexin receptor-modulatory compounds of the present invention can be used in treatment of an eating disorder, obesity, alcoholism or an alcohol-related disorder, drug abuse or addiction including addiction to cocaine, opiates, amphetamines, or nicotine, a sleep disorder, a cognitive dysfunction in a psychiatric or neurologic disorder, depression, anxiety, panic disorder, schizophrenia, Alzheimer's disease, Parkinson's disease, Huntington's chorea, headache, migraine, pain, gastrointestinal diseases, epilepsy, inflammations, immune-related diseases, endocrine-related diseases, cancer, hypertension, behavior disorder, mood disorder, manic depression, dementia, sex disorder, psychosexual disorder, or renal disease.

  本发明涉及调节促觉醒肽受体（如OX1或OX2，或两者）生物活性的化合物；包含本发明化合物的药物组合物；在需要医学上调节促觉醒肽受体的疾病患者中治疗的方法；以及本发明化合物的制备方法。例如，本发明的促觉醒肽受体调节化合物可用于治疗进食障碍、肥胖症、酗酒或与酒精相关的障碍、药物滥用或成瘾（包括可卡因、鸦片类药物、安非他命或尼古丁成瘾）、睡眠障碍、精神或神经障碍中的认知功能障碍、抑郁症、焦虑症、惊恐症、精神分裂症、阿尔茨海默病、帕金森病、亨廷顿舞蹈症、头痛、偏头痛、疼痛、胃肠疾病、癫痫、炎症、免疫相关疾病、内分泌相关疾病、癌症、高血压、行为障碍、情感障碍、躁郁症、痴呆症、性障碍、心理性性障碍或肾脏疾病的治疗。
• Difluoropyrrolidines as orexin receptor modulators
  申请人：Eolas Therapeutics, Inc.

  公开号：US10221170B2

  公开（公告）日：2019-03-05

  The present application relates to certain difluoropyrrolidine compounds, pharmaceutical compositions containing them, and methods of using them, including methods for treating substance addiction, panic disorder, anxiety, post-traumatic stress disorder, pain, depression, seasonal affective disorder, an eating disorder, or hypertension.

  本申请涉及某些二氟吡咯烷化合物、含有这些化合物的药物组合物以及使用这些化合物的方法，包括治疗药物成瘾、恐慌症、焦虑症、创伤后应激障碍、疼痛、抑郁症、季节性情感障碍、饮食失调或高血压的方法。
• DIFLUOROPYRROLIDINES AS OREXIN RECEPTOR MODULATORS
  申请人：Eolas Therapeutics Inc.

  公开号：EP3180332B1

  公开（公告）日：2021-10-27